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Abstract: Estrous cycle-related fluctuations in delta-9-tetrahydrocannabinol 
(THC)-induced antinociception have been observed in the rat. The aim of this 
study was to determine which major ovarian hormone modulates the 
antinociceptive effects of i.c.v. THC, and whether hormone modulation of 
THC's behavioral effects could be due to changes in brain cannabinoid 
receptors (CBr). Vehicle (oil) or hormones (estradiol or progesterone, or both) 
were administered to female rats on days 3 and 7 post-ovariectomy. On the 
morning or afternoon of day 8 or day 9, vehicle or THC (100 μg) was 
administered i.c.v. Paw pressure, tail withdrawal, locomotor activity and 
catalepsy tests were conducted over a 3-h period. Estradiol (with and without 
progesterone) enhanced THC-induced paw pressure antinociception only. 
Ovarian hormones time-dependently modulated CBr in brain structures that 
mediate antinociception and locomotor activity, but the changes observed in 
CBr did not parallel changes in behavior. However, the time course of CBr 
changes must be further elucidated to determine the functional relationship 
between receptor changes and antinociceptive sensitivity to THC. 
Keywords: Hormone. Female. Cannabinoid. Antinociception, Locomotion, 
Radioligand binding 
1. Introduction 
Behavioral effects of cannabinoids are sexually dimorphic, with 
female rats being more sensitive than males to the reinforcing, 
antinociceptive, sedative and cognition-impairing effects of 
cannabinoids (Tseng and Craft, 2001; Romero et al., 2002; Cha et al., 
2007; Fattore et al., 2007; Craft and Leitl, 2008; Wakley and Craft, 
2011; Craft et al., 2012). Sex differences in antinociceptive response 
to cannabinoids such as delta-9-tetrahydrocannabinol (THC) may be 
explained by ovarian hormones. Estradiol (E2) enhanced systemic 
THC-induced antinociception in ovariectomized (OVX) females 
compared to OVX females without hormone replacement (Craft and 
Leitl, 2008). This enhancement was similar to that observed in 
gonadally intact females tested in estrus vs. those tested in diestrus 
(Craft and Leitl, 2008). Estrous stage also modulates antinociception 
following supraspinal THC administration: females in late proestrus 
showed greater paw pressure antinociception than females in estrus 
and males (Wakley and Craft, 2011). These studies demonstrate that 
ovarian hormones likely contribute to sex and estrous stage-related 
differences in cannabinoid antinociception. 
Ovarian hormones also influence endocannabinoid signaling. E2 
decreased pituitary cannabinoid receptor (CBr) mRNA levels in OVX 
females (González et al., 2000). Similarly, acute E2 decreased Gα 
protein activation in the cortex and hippocampus of prepubescent 
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female rats (Mize and Alper, 2000). In the limbic forebrain, 
ovariectomy decreased, and E2 increased CBr density (Bonnin et al., 
1993; Rodriguez De Fonseca et al., 1994). Similarly, ovariectomy 
decreased CBr density in amygdala but increased it in the 
hypothalamus and hippocampus; E2 reversed these changes (Riebe et 
al., 2010). The other major ovarian hormone, progesterone (P4), 
increased CBr density in the limbic forebrain and midbrain but 
decreased it in the striatum of OVX females; however, when P4 was 
given with E2, hypothalamic CBr density was increased (Rodriguez De 
Fonseca et al., 1994), suggesting that P4 can reverse E2's effects. 
Although hormone modulation of the brain endocannabinoid system is 
a likely mechanism underlying ovarian hormone enhancement of the 
behavioral effects of cannabinoids in females, hormone effects appear 
to be brain structure-dependent and hormone-specific. 
Previous studies examining ovarian hormone modulation of the 
endocannabinoid system and the behavioral effects of cannabinoids 
have used hormone regimens that do not mimic natural hormone 
fluctuations in a gonadally intact female. Typically, a single hormone 
was administered, and effects were examined at a single time point 
thereafter (Bonnin et al., 1992, 1993; Rodriguez De Fonseca et al., 
1994; Craft and Leitl, 2008; Kalbasi Anaraki et al., 2008; Riebe et al., 
2010). During the 4- to 5-day estrous cycle of a rat, E2 and P4 peak in 
early and late proestrus, respectively (Smith et al., 1975; Feder, 
1981; Freeman, 1988). Thus, in the present study a modified cyclic 
hormone regimen (Asarian and Geary, 2002) was used to determine 
which ovarian hormone is responsible for the enhanced supraspinal 
THC-induced antinociception previously observed in gonadally intact, 
late proestrous females (Wakley and Craft, 2011). The goals of the 
present research were to determine if: 1) E2, P4 or both are 
responsible for increased supraspinal THC-induced antinociception; 
and 2) cyclic ovarian hormones modulate CBr density/affinity in brain 
areas known to mediate antinociception. 
2. Materials and methods 
To examine cyclic ovarian hormone modulation of THC's effects 
in females, we measured the effect of i.c.v. THC on antinociception 
and motor behavior (Experiment 1), and on CBr density and affinity in 
brain structures known to mediate antinociception and motor behavior 
(Experiment 2). A third experiment was conducted to measure actual 
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serum hormone levels in females treated with the cyclic hormone 
regimen. 
2.1. Subjects 
Adult female Sprague–Dawley rats were used (60–100 days old, 
bred in-house from Taconic stock, Germantown, NY). Ad libitum access 
to food and water was provided except during surgery and testing. 
Rats were housed in a room with a 12:12 h light/dark cycle (lights on 
at 0600 h), maintained at 21 ± 2°C. Pair-housing was implemented 
until surgery, after which rats were singly housed to avoid damage to 
the intracranial implant. This housing procedure was also implemented 
for rats used in Experiments 2 and 3. Animals were treated in 
accordance with the Guide for the Care and Use of Laboratory Animals 
(National Research Council, 2011). 
2.2. Surgery 
All rats were ovariectomized as described previously (Stoffel et 
al., 2003; Craft and Leitl, 2008). For Experiment 1 only, a guide 
cannula was also surgically implanted into the right lateral ventricle of 
all rats. First, s.c. chlordiazapoxide (3 mg/kg; Sigma Aldrich, St. Louis, 
MO) and pre-operative morphine (0.5 mg/kg; Sigma Aldrich, St. Louis, 
MO) were injected; 15 min later, rats were anesthetized with 
90 mg/kg ketamine hydrochloride plus 10 mg/kg xylazine i.p. 
(Webster Veterinary Supply Inc., Kansas City, MO). A 22-gauge 
cannula (Plastics One, Roanoke, VA) was implanted into the right 
lateral ventricle (AP—1.3 mm; ML—1.8 mm; DV—3.4 mm) (Krivsky et 
al., 2006; Paxinos and Watson, 2007). Surgery duration was 
approximately 20 and 25 min for ovariectomy and cannula guide 
implantation, respectively. Post-operative morphine (2.0 mg/kg) then 
was administered. Behavioral testing (Experiment 1) or tissue and 
serum collection (Experiments 2 and 3) occurred 8–9 days after 
surgery. 
2.3. Cyclic hormone administration 
Estradiol-3-benzoate (E2) and progesterone (P4; Steraloids, 
Newport, RI) were dissolved in safflower oil, which served as the 
vehicle for both hormones. Vehicle and hormones were administered in 
a 0.1-mL volume. In all experiments, on post-surgery days 3 and 7 at 
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0700 h, either safflower oil (vehicle control) or E2 (2 μg) was 
administered s.c. to each female. Ten hours later, a second s.c. 
injection of either safflower oil or P4 (500 μg) was administered (see 
Fig. 1). This cyclic hormone regimen was based on one used by 
Asarian and Geary (Asarian and Geary, 2002) to mimic the natural 
fluctuation of E2 in gonadally intact, cycling females; the regimen was 
modified to include a P4 injection to also mimic fluctuating P4 levels 
found in cycling females. P4 was administered 10 h after E2 based on 
previous research showing that P4 levels peak 8–12 h after E2 levels 
in gonadally intact, cycling female rats. (Smith et al., 1975; Feder, 
1981; Freeman, 1988; Haim et al., 2003) Rats in Experiment 1 were 
randomly assigned to one of four hormone conditions (oil + oil, 
oil + P4, E2 + oil, or E2 + P4) and rats in Experiment 2 were randomly 
assigned to one of two hormone conditions (oil + oil or E2 + P4) based 
on results from Experiment 1. All rats in Experiment 3 were treated 
with both E2 and P4. 
 
Fig. 1. Schematic representation of procedure for behavioral experiment (Experiment 
1). On post-surgery days 3 and 7, females were given s.c. injections (dashed arrows) 
of oil or estradiol (E2) at 0700 and then 10 h later (1700) given oil or progesterone 
(P4). On days 8 and 9, separate groups of females were tested at 0800 and 1500 
(solid arrows). 
2.4. Experiment 1: Cyclic ovarian hormone modulation 
of ICV THC antinociception and motor behavior 
Once two cycles of hormones were given (post-surgery days 3 
and 7), behavioral testing was conducted at one of three time points 
following the last hormone (or oil) injection (see below). Each rat was 
tested in only one hormone condition, with either vehicle or THC, at 
one of the three time points. Rats were tested starting at 15 h (0800 h 
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on post-surgery day 8: “day 8, AM”), or 22 h (1500 h on post-surgery 
day 8: “day 8, PM”), or 39 h (0800 h on post-surgery day 9: “day 9, 
AM”) after the last hormone (or oil) injection (see Fig. 1). These time 
points were chosen to capture the onset and offset of hormonal 
modulation of supraspinal THC-induced antinociception, based on a 
pilot study. There were 12–13 rats in each vehicle-treatment group 
and 15–16 rats in each THC-treatment group (day, dose, hormone 
condition) that were included in the final analysis. Baseline latency to 
respond was obtained by testing each subject on the tail withdrawal 
and paw pressure assays in that sequence, three times. For the tail 
withdrawal assay, the distal 5 cm of the tail was submerged in a 
50 ± 0.5 °C warm water bath (2.5-L; Precision Scientifics Inc., 
Winchester, VA) and latency to withdraw the tail was measured to the 
nearest 0.01 s using a stopwatch. A cutoff of 20 s was used to avoid 
tissue damage. Paw pressure antinociception was assessed using an 
Analgesy-meter (Ugo-Basile, Varese, Italy). The pressure on the paw 
began at 30 g and increased at a constant rate of 48 g/s to a 
maximum of 990 g (20 s). Latency to withdraw or attempt to withdraw 
the hindpaw was measured to the nearest 0.1 s and a cutoff of 20 s 
was used. 
After baseline testing, vehicle (1:1:8 ethanol/cremophor/saline) 
or 100 μg THC (National Institute on Drug Abuse, Bethesda, MD) was 
administered i.c.v. in a volume of 5 μL, at a rate of 20 μL/min; the 
injector was left in place for 1 min following infusion to reduce 
backflow up the cannula. Only one dose of THC was examined due to 
solubility limitations. Rats were then tested for tail withdrawal and paw 
pressure antinociception at 5, 15, 30, 60, 120 and 180 min post-
injection. Horizontal locomotor activity was measured using a 
photobeam apparatus (Opto-varimex, Columbus Instruments, 
Columbus, OH) in which 15 photobeams (spaced 2.5 cm apart and 
8 cm above the cage floor) cross the width of a 20 × 40 × 23-cm clear 
Plexiglas rodent cage. Locomotor activity was measured as the number 
of photobeams broken in a 5-min period, beginning immediately after 
nociceptive testing at 15, 30, 60, 120 and 180 min post-injection. 
Catalepsy (cutoff of 12 s) was assessed at 15 and 30 min post-
injection only, to avoid practice effects. For the catalepsy test, the 
rat's forepaws were placed on a bar (ring stand with a 1.5-cm 
diameter horizontal bar set at approximately 12 cm above the table 
surface) and latency to remove both paws from the bar or jump onto 
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the bar was recorded to the nearest 0.01 s. Rats were returned to 
their home cage between testing periods. 
Five to 10 min prior to the first baseline test and immediately 
after all behavioral testing was complete, a vaginal cell sample was 
obtained from each female via lavage to verify hormone manipulation. 
Proestrus (Pro) was identified by the predominance (approximately 
75% or more of cells in the sample) of nucleated epithelial cells; 
proestrus to estrus (P/E, sometimes referred to as “late proestrus”) 
(Bradshaw et al., 2006) was identified by approximately equal 
proportions of nucleated and cornified epithelial cells; estrus (Est) was 
identified by the presence of dense sheets of cornified epithelial cells; 
and diestrus (Diest) was identified by scattered nucleated and cornified 
epithelial cells and leukocytes (diestrus-1) or a relative lack of any 
cells (diestrus-2) (Freeman, 1988). 
Following the last vaginal lavage, rats were euthanized and then 
decapitated. Giemsa dye (~ 0.10 mL, Sigma-Aldrich, St. Louis, MO) 
was injected into the cannula and the brain was extracted and 
sectioned to verify cannula placement. Uteri were harvested, fixed in 
10% formalin, and later trimmed and weighed. 
2.5. Experiment 2: Membrane preparation and 
[3H]SR141716A binding assays 
Based on the results from the behavioral experiment 
(Experiment 1), tissue for the radioligand binding study was taken 
from separate groups of oil + oil-treated and E2 + P4-treated rats, 
either 15 h (0800 h on post-surgery day 8: “day 8, AM”—when 
hormone enhancement of THC's effect was first observed) or 46 h 
(1500 h on post-surgery day 9: “day 9, PM”—when hormone 
enhancement of THC's effect was no longer evident) after the last oil 
or hormone injection. Brains were quickly removed and placed on ice. 
The caudate putamen, hypothalamus, amygdala, periaqueductal gray 
(PAG) and cerebellum were immediately dissected. These structures 
were chosen because they have been shown to mediate cannabinoid 
antinociception (Lichtman et al., 1996; Martin et al., 1999) and 
motoric effects (Gough and Olley, 1977; Dar, 2000; Shi et al., 2005). 
Tissues were frozen in liquid nitrogen and stored at − 80 °C until 
protein estimation and binding was conducted. 
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Brain tissues were thawed and homogenized in 700 μL TME 
buffer (28 mM Tris–HCl, 22 mM Tris Base, 3 mM MgCl2, 1 mM EDTA, 
pH 7.4). PAG tissue was pooled from two females in the same 
condition in order to obtain sufficient protein concentration for each 
assay. Homogenates were centrifuged twice at 15,000g for 25 min at 
4°C and the remaining pellet was re-suspended in the same volume of 
TME buffer. Protein concentrations were determined by the Pierce BCA 
method (Thermo Scientific, Rockford, IL, USA) using bovine serum 
albumin (BSA) as a standard. 
Saturation binding analysis was conducted by incubating 25 μg 
membrane protein with 0.1–10 nM [3H]SR141716A (Perkin Elmer, 
Waltham, MA, USA) in TME buffer containing 0.5 g/L fatty acid free 
BSA in a final volume of 0.5 mL (Kearn et al., 1999; Breivogel, 2006; 
Wiley et al., 2008). Non-specific binding was determined by the 
presence of 1 μM of unlabeled SR141716A (National Institute on Drug 
Abuse, Bethesda, MD, USA). Assays were conducted in duplicate and 
incubated at 30°C for 60 min (with gentle agitation). Using a harvester 
(Brandel, Gaithersburg, MD, USA), incubation was terminated by rapid 
filtration under vacuum through Whatman GF/B glass fiber filters that 
had been soaked in TME buffer containing 5 g/L fatty acid free BSA. 
Filters were washed three times with ice-cold TME buffer containing 
2 g/L fatty acid free BSA. Bound radioactivity was determined by liquid 
scintillation spectrophotometry at 60% efficiency for 3H after 
extraction of the filters in 3 mL of scintillation fluid (EcoScint, National 
Diagnostics, Atlanta, GA, USA). Bmax (maximal binding site density) 
and KD (equilibrium dissociation constant) were determined by 
nonlinear curve fitting of data to the one-site binding equation (Sigma 
Plot Version 11.0). 
2.6. Experiment 3: Radioimmunoassays to determine 
serum hormone levels 
To examine E2 and P4 serum levels at various time points after 
injection, a separate group of females was treated with two cycles of 
E2 + P4 as described above. Trunk blood was taken from 6–8 
rats/time point, at the same times that behavioral testing was 
conducted (15, 22, 39, and 46 h after the last hormone/oil injection), 
plus at several earlier time points (4 and 6 h after the last E2 and P4 
injections), to capture peak hormone levels. Blood samples were 
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centrifuged for 20 min at 2000 rpm at 4°C; serum was removed and 
stored at − 80°C until analysis. Hormone levels were determined via 
double antibody radioimmunoassay kits (estradiol (Cat # KE2D1) and 
progesterone (Cat # TKPG1): Siemens Healthcare Diagnostics, Los 
Angeles, CA, USA). Manufacturer's instructions were followed except 
for the E2 assay, in which samples and standards were extracted twice 
using methyl tert butyl ether (done in duplicate); after the ether 
evaporated, the antibody was added to the extraction tubes, which 
were incubated for 24 h at 4°C, followed by addition of the tracer and 
then overnight incubation. 
2.7. Data analysis 
In Experiment 1, only data from rats determined to have 
accurate cannula placements were included in analyses (N = 19 were 
removed). If post-injection backflow of fluid (possibly vehicle or THC) 
from the cannula was observed and less than 40% antinociception was 
observed on either nociceptive assay, all data from that rat were 
removed before any analysis (N = 2 from oil + oil group; N = 7 from 
E2 + oil group; N = 6 from oil + P4 group; N = 3 from E2 + P4 
group). Vaginal samples from three females treated with oil + oil or 
oil + P4 indicated that they were in proestrus or estrus during testing, 
suggesting that an ovary was not fully removed; all data from these 
rats were removed before analysis. Baseline nociceptive latencies for 
each rat on the tail withdrawal and paw pressure tests were calculated 
as the mean of the three pre-injection trials. Individual nociceptive 
response latencies following vehicle or drug administration were 
converted to % maximum possible effect (%MPE): (drug 
latency − baseline latency)/(cutoff latency − baseline latency) × 100. 
Time course %MPE data for both tail withdrawal and paw pressure 
were converted to area-under-the-curve (AUC) values using the 
trapezoidal rule. Because there were differences in locomotor activity 
across days in vehicle-treated rats, locomotor activity data in THC-
treated rats were converted to % control, on each test day: (# 
photobeam breaks in THC-treated rat/mean # photobeam breaks in 
same-hormone, same-day, vehicle-treated control group) × 100. 
Percent of control locomotor activity data were also converted to AUC 
values. A catalepsy score for each rat was obtained by averaging 
response latencies at 15 and 30 min post-injection. Some rats 
displayed behaviors that were incompatible with catalepsy (i.e., barrel 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Pharmacology Biochemistry and Behavior, Vol 124, (September 2014): pg. 269-277. DOI. This article is © Elsevier and 
permission has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission 
for this article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier. 
10 
 
rolling, horizontal rocking, loss of muscle tone, lateral head movement 
or alternating forepaw movements) at one time point; for those rats a 
single catalepsy score was used for analysis. Because there were 
significant differences in catalepsy scores among vehicle-treated rats 
in the different hormone groups, catalepsy scores were converted to 
difference scores (catalepsy score for each THC-treated rat − mean 
catalepsy score for vehicle-treated controls in the same hormone 
group) before analysis. To control for differences in uterine weight that 
were due to differences in body weight, uterine weights (g) were 
divided by the rat's body weight in kg, before analysis. 
For Experiment 1, antinociception AUC values and uterine 
weight were analyzed using a four-way ANOVA: day (3 levels), THC 
dose (2 levels), E2 (2 levels), and P4 (2 levels). Locomotor AUC values 
and catalepsy data were analyzed using a three-way ANOVA: day (3 
levels), E2 (2 levels), and P4 (2 levels). Post-hoc comparisons were 
conducted using Bonferroni for comparison across days or two-way 
ANOVA for comparisons across hormone groups at different time 
points. 
For Experiment 2, Bmax and KD values for each brain structure 
were analyzed using a two-way ANOVA: day (2 levels) and hormone 
treatment (2 levels). Post-hoc comparisons were conducted using t-
tests to compare across day and hormone treatment. For Experiment 
3, a one-way ANOVA was used to compare serum levels of each 
hormone over time. Significance level was P ≤ 0.05 for all statistical 
tests. 
3. Results 
3.1. Experiment 1: Cyclic ovarian hormone modulation 
of THC's effects on antinociception and motor behavior 
3.1.1. Baseline (non-drug) responding 
Average baseline tail withdrawal latency across all groups was 
5.53 ± 0.04 s. Baseline tail withdrawal latency significantly differed 
between rats tested on different days (data not shown; F(2, 
133) = 3.69, P < 0.05): tail withdrawal latencies in rats tested on day 
8, PM (5.69 ± 0. 12) were higher than those tested on day 9, AM 
(5.24 ± 0.12) (P < 0.05). However, when tail withdrawal latencies 
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were compared across the 180-min test period in rats given vehicle 
(1:1:8 ethanol/cremophor/saline), latency did not differ significantly 
among the four hormone groups on any of the test days. Average 
baseline paw pressure latency across all groups was 4.31 ± 0.04 s and 
did not differ significantly among rats tested on the different days or 
given different hormones. Additionally, paw pressure latency did not 
differ in vehicle-treated rats across the 180-min test period regardless 
of hormone group or test day. 
3.1.2. Antinociception 
Fig. 2A shows i.c.v. THC-induced tail withdrawal antinociception 
in OVX females treated with oil, E2, P4, or both hormones, and tested 
15, 22, or 39 h after the last hormone or oil injection (i.e., on post-
surgery day 8, AM, day 8, PM or day 9, AM). THC produced tail 
withdrawal antinociception (THC dose: F(1, 310) = 246.74, 
P < 0.001). Neither hormone, given alone or in combination, altered 
THC-induced tail withdrawal antinociception on any of the test days 
examined, nor were any significant interactions observed. Although P4 
appeared to blunt THC-induced tail withdrawal antinociception on day 
8, AM (Fig. 2A), this effect was not statistically significant (P4 × THC 
dose × day: F(2, 310) = 0.55, ns). Fig. 2B shows that i.c.v. THC 
produced paw pressure antinociception (THC dose: F(1, 
310) = 250.03, P < 0.001). E2 significantly enhanced THC's 
antinociceptive effect (E2 × THC dose: F(1, 310) = 4.33, P < 0.05), 
with no significant day or P4 interactions (E2 × THC dose × day: F(2, 
310) = 0.17, ns; E2 × P4 × THC dose × day: F(2, 310) = 0.98, ns). 
 
Fig. 2. Area-under-the-curve (AUC) values for i.c.v. THC-induced tail withdrawal (A) 
and paw pressure (B) antinociception in cyclic hormone groups tested 15, 22, or 39 h 
after the last hormone (or oil) injection (i.e., on post-surgery day 8, AM, day 8, PM or 
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day 9, AM). Each bar is the mean ± 1 SEM of 12–16 rats. When collapsed across days 
and E2 group (E2 alone and E2 + P4), E2 significantly enhanced paw pressure 
antinociceptive effect of THC (P < 0.05). 
3.1.3. Locomotor activity 
Locomotor activity in vehicle-treated rats differed among groups 
tested at each day (data not shown; day: F(2, 310) = 8.43, 
P < 0.001). Specifically, locomotor activity was significantly lower on 
day 8, PM than on day 8, AM (P < 0.001) and on day 9, AM 
(P < 0.05). Neither hormone significantly altered locomotor activity 
AUC values on any test day, nor were any significant interactions 
observed (Fig. 3A; E2 × P4 × day: F(2, 177) = 0.20, ns; P4 × day: 
F(2, 177) = 1.15, ns). 
 
Fig. 3. Area-under-the-curve (AUC) values for i.c.v. THC-induced locomotor 
suppression (A) and catalepsy difference scores 15–30 min after i.c.v. THC (B) in 
cyclic hormone groups tested 15, 22, or 39 h after the last hormone (or oil) injection 
(i.e., on post-surgery day 8, AM, day 8, PM or day 9, AM). Locomotor data are 
presented as the percentage of same-hormone group, vehicle-treated controls. 
Catalepsy data are presented as the difference scores between THC-treated rats and 
vehicle-treated controls (see Data Analysis section). Each bar is the mean ± 1 SEM of 
12–16 rats. 
3.1.4. Catalepsy 
Average time spent on the bar for i.c.v. vehicle-treated females 
in the oil + oil, oil + P4, E2 + oil and E2 + P4 groups across all days 
was 1.10 ± 0.09, 1.16 ± 0.09, 1.33 ± 0.13 and 1.50 ± 0.16 s, 
respectively. E2-induced increases in time spent on the bar were 
significant in i.c.v. vehicle-treated females (Fig. 3B; E2: F(1, 
120) = 4.45, P < 0.05). Fig. 3B shows the catalepsy difference scores 
for THC-treated females. Neither hormone, given alone or in 
combination, significantly altered THC-induced catalepsy on any day, 
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nor were there any significant interactions. It should be noted that 
other motoric effects of THC were observed in some rats: barrel-rolling 
or involuntary spinning of the whole body (Kelly et al., 1977; Wakley 
and Craft, 2011), and/or horizontal rocking and loss of muscle tone 
were observed in 33% of rats given THC (Table 1). Although barrel 
rolling was observed in 25% of the E2 + P4-, THC-treated rats, 
approximately 18% of the oil + oil-, THC-treated rats displayed the 
same behavior. 
Table 1. Percent of THC-treated rats showing various motoric effects during 
the 15- and/or 30-min post-injection catalepsy measurements (# rats 
showing behavior/total # rats tested), and catalepsy score (mean ± 1 SEM, in 
seconds). 
Behavior Oil + Oil Oil + P4 E2 + Oil E2 + P4 
Loss of muscle 
tonea 4.3% (2/47) 10.9% (5/46) 10.4% (5/48) 8.3% (4/48) 
Horizontal 
rockingb 8.5% (4/47) 4.3% (2/46) 18.8% (9/48) 2.1% (1/48) 
Barrel-rollingb 19.0% (9/47) 6.5% (3/46) 10.4% (5/48) 25.0% (12/48) 
Catalepsyb 2.83 ± 0.33 (46/47) 
2.81 ± 0.39 
(46/46) 
3.98 ± 0.41 
(46/48) 
3.66 ± 0.39 
(46/48) 
aRat slipped off bar immediately after forepaws were placed on bar. 
bBehaviors are not mutually exclusive; i.e., a rat could show both loss of muscle tone 
and barrel-rolling behavior. 
 
3.1.5. Supraspinal effects of THC 46 h after the last hormone 
injection (day 9, PM) 
Because enhancement of paw pressure antinociception persisted 
out to day 9, AM, in E2 + P4-treated females (Fig. 2B), separate 
groups of females were treated with oil + oil or E2 + P4 and then were 
tested 46 h after the last hormone injection (day 9, PM) to determine 
if this enhancement waned. On day 9, PM, tail withdrawal and paw 
pressure AUC values were comparable between oil + oil and E2 + P4 
rats (data not shown; hormone × THC dose: F(1, 52) = 0.85, ns for 
tail withdrawal; hormone × THC dose: F(1, 52) = 0.05, ns for paw 
pressure). Similarly, no hormone effects on THC-induced locomotor 
suppression or catalepsy were observed (data not shown; 
hormone × THC dose: F(1, 52) = 0.01, ns for locomotor activity; 
hormone × THC dose: F(1, 52) = 0.75, ns for catalepsy). However, 
uterine weights of E2 + P4-treated females were still significantly 
increased compared to oil + oil-treated rats on day 9, PM (data not 
shown; hormone: F(1, 52) = 210.81, P < 0.001). Finally, on day 9, 
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PM, 54% of E2 + P4-treated rats were in Pro, 32% were in Est, and 
the remaining 14% were in P/E. 
3.1.6. Vaginal cytology 
Vaginal cytology was assessed both before and after the 3-h 
test period to obtain additional information regarding hormone status. 
Fourteen percent of females did not show the same vaginal cytology 
from pre-test to post-test and in these cases the pre-test cytology was 
used. Table 2 shows the percent of rats in each estrous stage in each 
hormone group across different test days. Oil-treated females 
(oil + oil) and P4-treated females (oil + P4) were all in the expected 
stage: 100% of all samples were diestrus (Diest). In contrast, 
approximately 75% of E2-treated rats (E2 + oil) were in proestrus 
(Pro) on day 8 (both AM and PM) with the remaining rats in either 
proestrus/estrus (P/E) or estrus (Est). On day 9, AM, E2-treated rats 
were predominately in Est (79%) with only 14% of samples showing 
vaginal cytology indicative of Pro. A majority of the rats (61%) treated 
with both E2 and P4 were in Pro on day 8, AM, with the remaining in 
either P/E or Est. However, only 21% of E2 + P4-treated rats tested 
on day 8, PM were in Pro; 50% were in Est. On day 9, AM, 78% of 
E2 + P4-treated rats were in either Pro or Est. 
Table 2. Pre-test estrous stage of rats in each hormone group, as % of rats 
showing vaginal cytology indicative of proestrus (Pro), proestrus/estrus (P/E), 
estrus (Est), or diestrus (Diest) (N = 28–29 rats/hormone group/day). 
Hormone treatment 
Day 8, AM Day 8, PM Day 9, AM 
Pro P/E Est Diest Pro P/E Est Diest Pro P/E Est Diest 
Oil + Oil 0 0 0 100 0 0 0 100 0 0 0 100 
Oil + P4 0 0 0 100 0 0 0 100 0 0 0 100 
E2 + Oil 75 14 11 0 72 14 14 0 14 4 82 0 
E2 + P4 61 18 21 0 21 11 68 0 39 14 47 0 
 
3.1.7. Uterine weight 
Fig. 4 shows that E2 significantly increased uterine weight (E2: 
F(1, 310) = 1611.37, P < 0.001). P4 attenuated E2's effect on uterine 
weight (E2 × P4: F(1, 310) = 13.01, P < 0.001). Females given THC 
also had lower uterine weights compared to those given vehicle (THC 
dose: F(1, 310) = 4.04, P < 0.05). 
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Fig. 4. Uterine weight (g/kg body weight) of cyclic hormone-treated OVX rats tested 
15, 22, or 39 h after the last hormone (or oil) injection (i.e., on post-surgery day 8, 
AM, day 8, PM or day 9, AM). Each bar is the mean ± 1 SEM of 12–16 rats. 
3.2. Experiment 2: Cyclic ovarian hormone modulation 
of CBr receptor binding and affinity 
Fig. 5 shows Bmax values and Table 3 shows KD values, for oil- 
vs. hormone-treated groups when brain tissue was harvested on day 
8, AM, or day 9, PM. These two time points were chosen as the earliest 
time at which hormone enhanced THC-induced antinociception and a 
later time point at which hormone had no effect on THC-induced 
antinociception in Experiment 1. Fig. 5A shows that in the PAG, 
E2 + P4 treatment increased Bmax on day 9, PM compared to oil-treated 
controls (hormone × day: F(1, 26) = 4.40, P < 0.05). Additionally, 
Bmax was decreased in day 9, PM oil-treated controls compared to day 
8, AM oil-treated controls (t(14) = 2.65, P < 0.05). In the PAG, 
changes in Bmax were not accompanied by changes in KD values 
(Table 3; hormone × day: F(1, 26) = 0.33, ns). Conversely, in the 
amygdala, neither day nor hormone treatment significantly affected 
Bmax or KD values (Fig. 5B and Table 3; all Ps > 0.05). 
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Fig. 5. Maximum binding capacity (Bmax) of cannabinoid receptors (CBr) in 
the periaqueductal gray (A), amygdala (B), caudate putamen (C), cerebellum 
(D) and hypothalamus (E) of OVX female rats treated with cyclic oil + oil or 
E2 + P4. Brain tissue was harvested 15 h (day 8, AM) or 46 h (day 9, PM) 
after the last oil or hormone injection. Each bar is the mean ± 1 SEM of 6–9 
rats/hormone group. *Significantly different from same-day, oil-treated 
females, P < 0.05. #Significantly different from oil-treated day 8, AM 
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females, P < 0.05. Note: The y-axis scale of cerebellum (D) is larger than 
other brain regions due to high density of CBr found in this structure. 
Table 3. Binding affinity of [3H]SR141716A (nM, mean ± 1 SEM) in 
OVX female rats treated with cyclic oil + oil or E2 + P4. 
Day 
 Brain structure 
Hormone 
group 
Caudate 
Putamen Amygdala Hypothalamus PAG Cerebellum 
Day 8, 
AM 
Oil + Oil 0.45 ± 0.04 0.39 ± 0.02 0.36 ± 0.03 
0.39 ± 
0.04 
0.54 ± 
0.06 
E2 + P4 0.35 ± 0.04 0.38 ± 0.04 0.45 ± 0.09 
0.39 ± 
0.06 
0.41 ± 
0.04 
Day 9, 
PM 
Oil + Oil 0.54 ± 0.06* 0.40 ± 0.04 0.43 ± 0.05 
0.34 ± 
0.03 
0.62 ± 
0.07 
E2 + P4 0.45 ± 0.03** 0.48 ± 0.06 0.40 ± 0.05 
0.42 ± 
0.05 
0.54 ± 
0.06 
Brain tissue collection occurred at 15 h (day 8, AM) or 46 h (day 9, PM) after 
the last oil or hormone injection. Each bar is the mean ± 1 SEM of 6–9 
rats/hormone group. 
*Significantly different from oil-treated day 8, AM females, P < 0.05. 
**Significantly different from same-day, oil-treated females, P < 0.05. 
 
Fig. 5C shows that in the caudate putamen, E2 + P4 treatment 
decreased Bmax compared to oil-treated controls only on day 9, PM 
(hormone × day: F(1, 27) = 4.45, P < 0.05). Unexpectedly, Bmax was 
increased in oil-treated day 9, PM females compared to oil-treated day 
8, AM females (t(13) = 2.61, P < 0.05). In the caudate putamen, 
E2 + P4 treatment also decreased KD compared to oil treatment 
(hormone: F(1, 27) = 6.39, P < 0.05), and KD values were decreased 
on day 8, AM compared to day 9, PM (Table 3; day: F(1, 27) = 6.06, 
P < 0.05). In the cerebellum, E2 + P4 treatment appeared to decrease 
Bmax; however, this effect was not significant (Fig. 5D; hormone: F(1, 
24) = 2.21, P = 0.15). Neither day nor hormone treatment 
significantly altered KD (all Ps > 0.05). Lastly, Fig. 5E and Table 3 
show that in the hypothalamus, day and hormone treatment did not 
alter Bmax or KD values (all Ps > 0.05). 
3.3. Experiment 3: Serum levels of E2 and P4 using a 
cyclic hormone regimen 
Fig. 6 shows that serum E2 reached peak levels by 16 h after 
the s.c. E2 injection given on day 7 at 0700 h, and levels were low by 
25 h after injection (time: F(7,47) = 2.99, P < 0.05). Serum P4 
reached peak levels by 4 h after the s.c. P4 injection given on day 7 at 
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1700 h, and levels declined over the next 18 h (Fig. 6; time: 
F(7,49) = 17.96, P < 0.001). 
 
Fig. 6. Serum levels of estradiol (E2; pg/mL) and progesterone (P4; ng/mL) 
at various points following hormone injections given on post-OVX day 7. Each 
point is the mean ± 1 SEM of 6 rats. 
4. Discussion 
The present study demonstrates that ovarian hormones alter 
sensitivity to supraspinal cannabinoid antinociception in female rats. In 
OVX females, E2 enhanced i.c.v. THC-induced mechanical 
antinociception, whether E2 was given alone or with P4. THC-induced 
antinociception was enhanced approximately 24–48 h after hormone 
injection. Ovarian hormones did not significantly modulate THC-
induced locomotor suppression or catalepsy, and therefore enhanced 
antinociception does not appear to be simply due to enhanced motoric 
effects. Ovarian hormones also altered CBr density in PAG and 
striatum and CBr affinity in striatum, but these changes did not 
parallel behavior in the predicted manner. 
The first finding, E2 enhancement of THC-induced mechanical 
antinociception, corroborates previous work from our laboratory. We 
first reported E2 enhancement of THC-induced antinociception 
following systemic THC administration in OVX female rats (Craft and 
Leitl, 2008). This hormone enhancement was similar to that observed 
in estrous compared to diestrous females receiving i.p. THC (Craft and 
Leitl, 2008), and in P/E compared to estrous females and males 
receiving i.c.v. THC (Wakley and Craft, 2011). The present study 
provides further evidence that E2 can act supraspinally to enhance 
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females' response to THC. Together, these studies indicate that sex 
and estrous stage differences in cannabinoid antinociception are due to 
E2 in females. 
In the present study, E2 enhanced only THC-induced mechanical 
antinociception. In all of our studies, THC-induced mechanical 
antinociception appears to be more sensitive than THC-induced 
thermal antinociception to ovarian hormone modulation (Tseng and 
Craft, 2001; Craft and Leitl, 2008; Wakley and Craft, 2011; Craft et 
al., 2012). E2 modulation of cannabinoid antinociception on one 
nociceptive test but not the other may reflect differences in the extent 
to which each nociceptive response engages spinal vs. supraspinal 
mechanisms. THC-induced tail withdrawal antinociception has been 
shown to be more spinally than supraspinally mediated (Smith and 
Martin, 1992). There is no direct evidence that the paw withdrawal 
response is supraspinally mediated, however, the postural adjustments 
required for this response likely involve supraspinal components (e.g., 
cerebellum, basal ganglia). Therefore, it is possible that E2 
enhancement of THC-induced antinociception was greater on the paw 
pressure than on the tail withdrawal assay due to a larger contribution 
of supraspinal mechanisms in the paw withdrawal response, and 
greater cannabinoid and/or E2 effects supraspinally than spinally. In 
the future, it will be important to determine whether E2 enhancement 
of cannabinoid antinociception can also occur at the spinal level, and 
whether this phenomenon is sensory modality-specific. 
This is the first study to examine the effects of ovarian 
hormones on CBr density and affinity in the PAG, a region of the brain 
involved in cannabinoid-mediated antinociception (Martin et al., 1995, 
1999; Lichtman et al., 1996). We found a significant increase in 
receptor density on day 9 PM but not on day 8 AM. Thus, hormone-
induced increases in CBr density did not parallel hormone-induced 
increases in behavioral sensitivity to THC. Further work will be 
necessary to fully characterize the time course of hormone-induced 
brain CBr changes, so that the temporal relationship between 
enhanced antinociception and CBr can be more precisely compared. 
Also, the effects of E2 alone on binding parameters need to be 
determined, as binding results from the present study are limited by 
examining only the E2 + P4-treated group. Finally, it is possible that a 
change in CBr density is not responsible or only partly responsible for 
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E2 enhancement of THC effect. Given the importance of PAG signaling 
in the antinociceptive effect of THC (Vaughan et al., 2000), it will be 
important to carefully examine the ability of ovarian hormones to 
upregulate CBr in this region. 
We also found significant ovarian hormone-dependent changes 
in binding parameters in the striatum. Interestingly, especially given 
the lack of significant interaction between hormones and THC on 
locomotor behavior, we found opposing changes in striatal binding 
parameters, with hormone decreasing CBr density but increasing 
affinity. These changes may be functionally related, with a change in 
one variable causing a subsequent response in the other, resulting in 
stable cannabinoid signaling. The fact that this ovarian hormone 
regimen produced both an increase and decrease in Bmax in different 
brain regions indicates that multiple regulatory pathways may be 
involved. Finally, we found no changes in CBr density or affinity in the 
hypothalamus, amygdala or cerebellum. 
Our methodology differs from previous investigations of the role 
of ovarian hormones on the regulation of CBr signaling. This is the first 
study to demonstrate that a cyclic hormone regimen (to mimic normal 
hormone fluctuation) produced changes in CBr density and affinity and 
that CBr density changes over time following ovariectomy. Although 
the effects of chronic and acute E2 or acute P4 on CBr in different 
brain regions have been examined previously (Bonnin et al., 1992, 
1993; Rodriguez De Fonseca et al., 1994; Riebe et al., 2010), only one 
has examined the combined effects of both ovarian hormones: 
E2 + P4 given simultaneously increased CBr density compared to oil-
treated controls, but only in the hypothalamus; no significant 
differences between the hormone group and oil-treated controls were 
observed in any other brain region (Rodriguez De Fonseca et al., 
1994). Furthermore, in the present study, E2 + P4 increased binding 
affinity in the caudate putamen, whereas (Rodriguez de Fonseca and 
colleagues 1994) did not find group differences in affinity in this brain 
region or any other. We utilized a cyclic hormone regimen (2 cycles of 
2 μg E2/rat and 500 μg P4/rat, with E2 and P4 given 10 h apart) with 
tissue collection at 15- and 46-h after the last hormone injection, 
whereas previous work used lower (0.02–0.03 μg E2/rat and 38–50 μg 
P4/rat) or higher (10 μg E2/rat) hormone doses; single or concomitant 
hormone injections; or a shorter pretreatment time, with tissue 
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collection occurring either 1 or 48 h after hormone injections 
(Rodriguez De Fonseca et al., 1994; Riebe et al., 2010). Taken 
together, the present and previous results suggest that ovarian 
hormones regulate expression of cannabinoid receptors in a highly 
time- and region-specific manner. 
Ovarian hormones could also enhance THC-induced 
antinociception through other mechanisms. For example, E2 may 
modulate cannabinoid effects through regulating N-type voltage-gated 
calcium channels (Lee et al., 2002; Adams et al., 2010) or other 
signaling mechanisms in the descending pain pathway to produce 
enhancement of THC antinociception. E2 has also been found to 
potentiate the presynaptic inhibition of GABA produced by WIN55,212 
in proopiomelanocortin neurons of the arcuate nucleus (Nguyen and 
Wagner, 2006), although the precise mechanism of this modulation 
remains unknown. If E2 produces a similar effect in the PAG, inhibiting 
the release of GABA such that output neurons are disinhibited, 
antinociception would be enhanced. 
Cyclic administration of E2 and P4 was used in the present study 
to mimic the normal hormone fluctuation of a gonadally intact cycling 
female rat. Although the time course of serum hormone levels was 
similar to that observed in cycling females, reproductive tissue indices 
revealed that this hormone regimen still was not precisely modeling a 
normally cycling female. Normally cycling females show peak levels of 
E2 and P4 between 40–45 pg/mL and 50–55 ng/mL, respectively, with 
E2 and P4 peaks approximately 8–12 h apart (Smith et al., 1975; 
Haim et al., 2003) – which is similar to what we observed in the 
present study. However, uterine weights and vaginal cytology did not 
show the progressive, rapid changes that are characteristic of cycling 
females post-ovulation, but instead were indicative of a lingering E2 
presence. Additionally, E2 enhancement of THC-induced 
antinociception in OVX females was prolonged compared to that 
observed in intact cycling females, occurring up to 49 h after the last 
E2 injection. In normal cycling females, the transition from late 
proestrus to estrus occurs in approximately 4 h (Feder, 1981) and 
enhancement of THC-induced antinociception in late proestrous 
females was absent in estrous females (Wakley and Craft, 2011). The 
prolonged effects of E2 on antinociception and on reproductive tissue 
were likely due to the use of estradiol-3-benzoate, which is longer-
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acting than 17β-estradiol (Becker et al., 2005). Consequently, 17β-
estradiol should be used to more accurately mimic natural cycling in 
females, as this would allow for more accurate characterization ovarian 
hormone modulation of drug sensitivity. 
In conclusion, the present study shows that the ovarian 
hormone E2 enhances female rats' sensitivity to supraspinal 
cannabinoid-induced antinociception. Using a cyclic hormone regimen, 
we found that E2 alone and in combination with P4 enhanced 
mechanical antinociception produced by i.c.v. THC, when THC's effects 
were measured approximately one day after E2 administration. 
Therefore, previously observed enhancement of i.c.v. THC in 
proestrous–estrous females is likely due to estradiol modulation of 
supraspinal mechanisms. Ovarian hormones did not modulate THC-
induced locomotor suppression or catalepsy, and therefore hormone 
effects on motor function do not appear to explain the observed 
enhancement of antinociception. Ovarian hormones time-dependently 
modulated CBr in brain structures that mediate antinociception and 
locomotor activity, but the changes observed in CBr did not parallel 
changes in behavior. Definitive causality between the receptor changes 
and enhanced sensitivity to THC cannot be ruled out since CBr density 
was only measured at the beginning and after the period of enhanced 
antinociception, rather than across the entire time course. Examination 
of hormone effects on downstream signaling of CBr may yield 
additional mechanistic explanations for hormone modulation of 
supraspinal cannabinoid effects. 
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